day 1 agenda
| World Congress on Vaccines July 10-11, 2025 @ Vienna, Austria |
||
| Meeting Hall - Karl Kraus+ Siegfried Marcus | ||
| 08:20-09:00 | Registrations | |
| 09:00-09:10 | Welcome Remarks by Moderator | |
| Moderator: Júlia Vergara-Alert, Institute of Agrifood Research and Technology, Spain | ||
| Keynote Talks | ||
| Liang Zhou, University of Florida, USA | 09:10-09:40 | The role of Innate Lymphoid Cells in Mucosal Infection |
| Monica Lahra, NSW Health Pathology, Australia | 09:40-10:10 | Multidrug resistant N. gonorrhoeae |
| Ying Liao, Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, China | 10:10-10:40 | Coronavirus Nucleocapsid Protein Enhances p-PKCα Binding to RACK1: Implications for Inhibition of Nucleocytoplasmic Trafficking and Suppression of the Innate Immune Response |
| Group Photo & Refreshment Break (10:40-11:00) | ||
| Technical Session-I | ||
| Session Chair : Liang Zhou, University of Florida, USA | ||
| Jooeun Bae, Harvard Medical School, USA | 11:00-11:20 | Combinational Immunotherapy with Multi-antigen targeting Cancer Vaccine |
| Sina Bavari, Tonix Pharmaceuticals Holding Corp, USA | 11:20-11:40 | TNX-801, a single-dose live vaccine platform for Mpox and other emerging viral diseases Safety, Immunogenicity, and Efficacy |
| Balázs Rada, The University of Georgia, USA | 11:40-12:00 | Opportunities for targeting neutrophils to increase vaccine efficacy |
| Tian Wang, University of Texas Medical Branch, USA | 12:00-12:20 | Development of safe and efficacious vaccines against emerging arboviruses |
| Lina Souan, King Hussein Cancer Center, Jordan | 12:20-12:40 | Effectiveness and Duration of Anti-RBD SARS-CoV-2 IgG Response Across Vaccines: Implications for Vaccine Strategies |
| Shin, Yeun-Kyung, Animal and Plant Quarantine Agency, South Korea | 12:40-13:00 | Propagation of porcine reproductive and respiratory syndrome virus increases in PRRSV-susceptible porcine kidney cells modifying LGP2 and RIG-I |
| Lunch Break @ Restaurant (13:00-14:00) | ||
| Technical Session-II | ||
| Session Chairs: Monica Lahra, NSW Health Pathology, Australia | ||
| Maja Mockenhaupt, University of Freiburg, Germany | 14:00-14:20 | Infections as possible trigger of epidermal necrolysis |
| Hamsa Taher Tayeb, King Faisal Specialist Hospital & Research Center, Saudi Arabia | 14:20-14:40 | Implementation of Next Generation Sequencing (NGS) as a Diagnostic Tool in Infectious Diseases |
| Polona Kogovšek, National institute of biology, Slovenia | 14:40-15:00 | Evaluation of the antiviral activity of compounds using computational, bioassay, molecular biology and electron microscopy techniques |
| Emmanuel Mintah Bonku, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, China | 15:00-15:20 | Progress in antiviral drug R&D, and API manufacturing via industrial-grade ‘control from root design’ concept |
| Ximeng Han, University of Oxford, United Kingdom | 15:20-15:40 | Preclinical Development of a Bivalent Malaria Transmission-Blocking Vaccine |
| Alessia Arcaro, University of Molise, Italy | 15:40-16:00 | Amhiphilic and ganglioside-binding properties of SARS-CoV-2 Spike glycoprotein variants dissected by charge-shift electrophoresis in detergent solution |
| Refreshment Break (16:00-16:20) | ||
| Poster Presentations(16:20-16:50) | ||
| Pooja Goel, The Lyndhurst Surgery, UK | P1 | Barriers to the Flu Vaccination: Patients’ Perspective within a London GP |
| Baek Kim, Vernagen LLC, USA | P2 | Immunogenicity and protective efficacy of Respiratory Syncytial Virus mRNA vaccine encoding the F protein of both RSV subtypes A and B in a BALB/c mouse model |
| Szu-Hao Kung, National Yang Ming Chiao Tung University, Taiwan | P3 | Development of ionophore antibiotics as antiviral agents against enteroviruses and coronaviruses |
| Pannel Discussions & Closing Ceremony | ||
day 2 agenda
| Day-2 (July 11, 2025) | ||
| Moderator: Tian Wang, University of Texas Medical Branch, USA | ||
| Keynote Talks | ||
| Jerald Sadoff, Centivax Inc, USA | 09:30-10:00 | Universal vaccines against influenza and other pathogens |
| Taijiao Jiang, Guangzhou National Laboratory, China | 10:00-10:30 | Predicting Influenza Virus Antigenic Variation and Vaccine Strains with PREDAC |
| Xiufen Zheng, Western University, Canada | 10:30-11:00 | Potentials and challenges of circular RNA as a therapy/vaccine in treating diseases |
| Refreshment Break (11:00-11:20) | ||
| Technical Session-III | ||
| Session Chairs: Xiufen Zheng, Western University, Canada Jerald Sadoff, Centivax Inc, USA |
||
| Lorrin Pang, Hawaii Dept of Health, USA | 11:20-11:40 | Accurately monitoring the effect of intervention tools during a pandemic (fixing the plane “while it’s flying") |
| Júlia Vergara-Alert, Institute of Agrifood Research and Technology, Spain | 11:40-12:00 | Zoo-in-a-dish. How organoids are reshaping zoonotic disease research |
| João Luis Garcia, Londrina State University, Spain | 12:00-12:20 | Vaccines against Toxoplasma gondii: the past, the present and the future |
| Yoon-Hee Lee, Animal and Plant Quarantine Agency, South Korea | 12:20-12:40 | The appication of Nano-Luciferase based biosensor for the detection of FMDV(Foot and Mouth Disease Virus) type Asia1 |
| I Y Saleem, Liverpool John Moores University, UK | 12:40-13:00 | Inhalable Nanovaccine Targeting Pneumococcal Proteins for Lung Protection |
| Ximeng Han, Jenner Institute, University of Oxford, UK | 13:00-13:20 | Preclinical Development of an Enhanced-Immunogenicity Pfs230-Pfs25 Malaria Transmission-Blocking Vaccine |
| Lunch Break @ Restaurant (13:20-14:20) | ||
| Day 2 Concludes | ||
| World Congress on Vaccines July 10-11 @ Vienna, Austria Scientific Program |
|
| Virtual Program | |
| July 11, 2025, Central European Time (CET) | |
| Virtual Presentation Through ZOOM | |
| 10:30-10:50 | A self-adjuvanted protein nanoparticle that stimulates Ultra-High affinity antibodies |
| Ming-Chung Kan, Vaxsia Biomedical Inc, Taiwan | |
| 10:50-11:10 | Synergistic effect of attenuated Toxoplasma gondii NRTUA strain and biological drug therapy: Reprogramming tumor microenvironment and inhibiting tumor growth in pancreatic cancer |
| Xingwang Zhou, Sun Yat-Sen University Zhongshan School of Medicine, China | |
| 11:10-11:30 | Broad-spectrum antiviral peptide studies against respiratory viruses |
| Hanjun ZHAO, Fudan University , Taiwan | |
| 11:30-11:50 | Immune correlates of Dengue protection and pathogenesis in pediatric Dengue infected patients |
| Anuja Krishnan, Jamia Hamdard University, India | |
| 11:50-12:10 | Post-vaccine immune status surveillance of Covishield vaccine and associated AEFI in previously SARS-Cov-2 infected seropositive and seronegative population in Assam |
| Gogoi, Gayatri, Assam Medical College and Hospital, India | |
| 12:10-12:30 | The influence of Anti-SARS-CoV-2 Vaccines on the Cytokine Responses of Peripheral Blood Mononuclear Cells and Neutrophils from Individuals Vaccinated with Pfizer and AstraZeneca |
| Sahar Sultan Essa, Kuwait University, Kuwait | |
| 12:30-12:50 | Does Delivery Matter? Examining Pandemic Vaccination Preferences across Time and Countries Using a Discrete Choice Experiment |
| Cynthia Qingxia Kong, Erasmus University, Netherlands | |
| 12:50-13:20 | Keynote: Possible mechanisms of centenarian resilience to COVID-19 |
| Calogero Caruso, University of Palermo, Italy | |
| 13:20-13:40 | Analysis of the expectations of patients with hepatitis c virus towards family doctors |
| Lidia El?bieta Sierpi?ska, Military Clinical Hospital, Poland | |
| 13:40-14:00 | Grassroots Mobilisation: Leveraging Civil Society and Community Leadership to Bridge Gaps in Vaccine Coverage |
| Mariano Votta, Responsible EU Affairs at Cittadinanzattiva, Italy | |
| 14:00-14:20 | Cwp2 as a vaccine candidate protects mice against Clostridioides difficile infection |
| Xingmin Sun, University of South Florida, Uk | |
| 14:20-14:50 | Keynote: Tuberculosis vaccination needs to avoid ‘decoy’ immune reactions |
| Juraj Ivanyi, Kings College London, UK | |
| 14:50-15:10 | TBA |
| Gisela Freitas Trindade, Oswaldo Cruz Foundation, Brazil | |
| 15:10-15:30 | The relationship between immunogenicity and reactogenicity of seasonal influenza vaccine using different delivery methods |
| Daniel Gromer, Emory University School of Medicine, United States | |
| 15:30-16:00 | Keynote: Mpox Outbreaks: Poxvirus Virulence Studies and Vaccine Development |
| Rachel Roper, East Carolina University, Brody Medical School, USA | |
| 16:00-16:30 | Keynote: Subunit nanovaccine elicited T cell functional activation controls Trypanosoma cruzi mediated maternal and placental tissue damage and improves pregnancy outcomes in mice |
| Nisha J Garg, Washington University, USA | |
| 16:30-16:50 | The neuroimmune mechanisms underlying SARS-CoV-2-induced post acute sequelae of COVID-19 |
| Jianyang Du, University of Tennessee Health Science Center, USA | |
| 16:50-17:10 | Assessing Biofilm at the Bedside: Exploring Reliable Accessible Biofilm Detection Methods |
| Laura Jones Donaldson, MolecuLight, Canada | |
| 17:10-17:40 | Keynote: Critical Role of Relative Humidity in the Survival and Transmission of Airborne Viruses |
| Richard N. Zare, Stanford University, Stanford, USA | |
| Day concludes | |